<DOC>
	<DOCNO>NCT01302340</DOCNO>
	<brief_summary>Dementia common chronic condition , predict increase prevalence . Nearly patient dementia experience neuropsychiatric symptom ( NPS ) . This cause significant burden individual patient caregiver . Current treatment modest efficacy important side-effects . Formulations Δ9-tetrahydrocannabinol ( THC ) , psycho-active compound cannabis , currently register spasms multiple sclerosis disease , may beneficial effect NPS .</brief_summary>
	<brief_title>Delta-THC Behavioral Disturbances Dementia</brief_title>
	<detailed_description>Design Phase II pilot study , multi-center , repeat cross-over , double blind randomize trial . The study consist two week baseline measurement assure neuropsychiatric symptom stable six successive treatment block 2 week . Each treatment block last two week contain two double-blinded drug period , last three day oral THC placebo , separate four day washout period . After three treatment block ( period A ) , dosage active treatment increase latter three treatment block ( period B ) . After two treatment period , subject proceed extension phase applicable . Study center The department Geriatrics Radboud University Nijmegen Medical Centre department Elderly Vincent van Gogh voor Geestelijke Gezondheidszorg Venray ( VVG ) participate multi center study . Participants 20 subject dementia NPS . Intervention Namisol® dose twice daily 0,75 mg tablet ( period A ) twice daily 1.5 mg ( period B ) THC oral tablet . Placebo twice daily 0,75 mg twice daily 1.5 mg oral tablet Outcome measure Primary outcome NPI score , secondary CMAI , Zarit Burden scale . Other outcome include vital sign , side-effects , physical exam , mobility pharmacogenetics . Visits This study assess fully ambulatory , start 5 hour clinical visit day 1 8 block 1 phone call day 2 9 assessment Adverse Events . Furthermore , research physician conduct weekly home visit weekly crossover phase assessment , among others , primary outcome measure . These visit repeat period B crossover phase . During 6 month open label extension phase , subject visit clinic three time .</detailed_description>
	<mesh_term>Dementia</mesh_term>
	<mesh_term>Problem Behavior</mesh_term>
	<mesh_term>Dronabinol</mesh_term>
	<criteria>Diagnosis Alzheimer 's Disease ( AD ) , Vascular Dementia ( VD ) mix , accord criterion NINCDSADRDA NINCDSAIREN Clinical Dementia Rating score 0.5 3 NPS symptom , least agitation aggression Diagnosis Lewy Body Dementia ( LBD ) FrontoTemporal Dementia ( FTD ) Major psychiatric disorder Severe concomitant illness , seizure , arrhythmia ( except sinus arrhythmia atrial fibrillation ) , heart failure New York Heart Association ( NYHA ) class III IV Tri Cyclic Antidepressives ( TCA ) opioids use within 30 day randomization till end study Changes dosage antidepressives within 6 week randomization study , change dosage antipsychotic benzodiazepine within 2 week prior randomization study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>Dementia</keyword>
	<keyword>Alzheimer</keyword>
	<keyword>Cannabis</keyword>
	<keyword>THC</keyword>
	<keyword>Behavioral Disturbances</keyword>
	<keyword>Neuropsychiatric Inventory</keyword>
</DOC>